You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameErgonovine
Accession NumberDB01253
TypeSmall Molecule
GroupsApproved
DescriptionAn ergot alkaloid with uterine and vascular smooth muscle contractile properties. [PubChem]
Structure
Thumb
Synonyms
(6AR,9R)-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
[8beta(S)]-9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide
9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide
9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide
D-Lysergic acid 1-hydroxymethylethylamide
D-Lysergic acid-L-propanolamide
Ergobasine
Ergometrina
Ergometrine
Ergometrinum
Ergonovine
Ergotrate maleate
N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide
N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ergonovine Maleate InjectionSolution0.25 mgIntramuscular; IntravenousMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Ergonovine Maleate InjectionSolution0.25 mgIntramuscular; IntravenousTeligent Ou2016-02-19Not applicableCanada
Ergonovine Maleate InjectionSolution.25 mgIntramuscular; IntravenousHospira Healthcare Corporation1981-12-31Not applicableCanada
Ergonovine Maleate Injection USP, 0.25mg/mlSolution0.25 mgIntramuscular; IntravenousAlveda Pharmaceuticals Inc2010-06-01Not applicableCanada
Ergotrate Maleate Tablet 1572 0.2mgTablet.2 mgOralEli Lilly Canada Inc1939-12-311998-08-04Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ErgotrateNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ergonovine maleate
ThumbNot applicableDBSALT001151
Categories
UNIIWH41D8433D
CAS number60-79-7
WeightAverage: 325.4048
Monoisotopic: 325.179026995
Chemical FormulaC19H23N3O2
InChI KeyWVVSZNPYNCNODU-XTQGRXLLSA-N
InChI
InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1
IUPAC Name
(4R,7R)-N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
SMILES
[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[[email protected]](CN2C)C(=O)N[C@@H](C)CO
Pharmacology
IndicationUsed to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony.
Structured Indications
PharmacodynamicsErgonovine belongs to the group of medicines known as ergot alkaloids. These medicines are usually given to stop excessive bleeding that sometimes occurs after abortion or a baby is delivered. They work by causing the muscle of the uterus to contract.
Mechanism of actionErgonovine directly stimulates the uterine muscle to increase force and frequency of contractions. With usual doses, these contractions precede periods of relaxation; with larger doses, basal uterine tone is elevated and these relaxation periods will be decreased. Contraction of the uterine wall around bleeding vessels at the placental site produces hemostasis. Ergonovine also induces cervical contractions. The sensitivity of the uterus to the oxytocic effect is much greater toward the end of pregnancy. The oxytocic actions of ergonovine are greater than its vascular effects. Ergonovine, like other ergot alkaloids, produces arterial vasoconstriction by stimulation of alpha-adrenergic and serotonin receptors and inhibition of endothelial-derived relaxation factor release. It is a less potent vasoconstrictor than ergotamine. As a diagnostic aid (coronary vasospasm), ergonovine causes vasoconstriction of coronary arteries.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-1A adrenergic receptorProteinyes
agonist
HumanP35348 details
Related Articles
AbsorptionAbsorption is rapid and complete after oral or intramuscular administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationThought to be eliminated by non-renal mechanisms (i.e. hepatic metabolism, excretion in feces)
Half lifet1/2 α=10 minutes; t1/2 β=2 hours
ClearanceNot Available
ToxicityThe principal symptoms of overdose are convulsions and gangrene. Other symptoms include bradycardia, confusion, diarrhoea, dizziness, dyspnoea, drowsiness, fast and/or weak pulse, miosis, hypercoagulability, loss of consciousness, nausea and vomiting, numbness and coldness of the extremities, pain in the chest, peripheral vasoconstriction, respiratory depression, rise or fall in blood pressure, severe cramping of the uterus, tachycardia, tingling, and unusual thirst.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Ergonovine can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Ergonovine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Ergonovine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AcebutololAcebutolol may increase the vasoconstricting activities of Ergonovine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Ergonovine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ergonovine.Approved, Vet Approved
AdrafinilErgonovine may increase the hypertensive activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ergonovine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ergonovine.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ergonovine.Approved, Investigational
AlmotriptanErgonovine may increase the vasoconstricting activities of Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Ergonovine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Ergonovine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprenololAlprenolol may increase the vasoconstricting activities of Ergonovine.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ergonovine.Approved, Investigational
AmiodaroneThe metabolism of Ergonovine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amisulpride.Approved, Investigational
AmitrazErgonovine may increase the hypertensive activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergonovine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergonovine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Ergonovine can be increased when it is combined with Amprenavir.Approved
AnisodamineErgonovine may increase the hypertensive activities of Anisodamine.Investigational
Antithrombin III humanThe serum concentration of Ergonovine can be increased when it is combined with Antithrombin III human.Approved
Aop200704Aop200704 may increase the vasoconstricting activities of Ergonovine.Investigational
ApixabanThe serum concentration of Ergonovine can be increased when it is combined with Apixaban.Approved
ApomorphineErgonovine may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineErgonovine may increase the hypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Ergonovine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Ergonovine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineErgonovine may increase the hypertensive activities of Arbutamine.Approved
ArformoterolErgonovine may increase the hypertensive activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Ergonovine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the vasoconstricting activities of Ergonovine.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ergonovine.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Ergonovine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Ergonovine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the vasoconstricting activities of Ergonovine.Approved
AtomoxetineThe metabolism of Ergonovine can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ergonovine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Azaperone.Vet Approved
BatimastatThe serum concentration of Ergonovine can be increased when it is combined with Batimastat.Experimental
BefunololErgonovine may increase the hypertensive activities of Befunolol.Experimental
BenazeprilThe serum concentration of Ergonovine can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Ergonovine can be increased when it is combined with Benzamidine.Experimental
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ergonovine.Approved, Vet Approved
BetaxololBetaxolol may increase the vasoconstricting activities of Ergonovine.Approved
BevantololBevantolol may increase the vasoconstricting activities of Ergonovine.Approved
BexaroteneThe serum concentration of Ergonovine can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Ergonovine can be increased when it is combined with Bi201335.Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Ergonovine is combined with Bifeprunox.Investigational
BisoprololBisoprolol may increase the vasoconstricting activities of Ergonovine.Approved
BitolterolErgonovine may increase the hypertensive activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Ergonovine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Ergonovine can be increased when it is combined with Boceprevir.Approved
BopindololBopindolol may increase the vasoconstricting activities of Ergonovine.Approved
BortezomibThe metabolism of Ergonovine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ergonovine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ergonovine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergonovine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Brexpiprazole.Approved
BrimonidineErgonovine may increase the hypertensive activities of Brimonidine.Approved
BromocriptineErgonovine may increase the vasoconstricting activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Bromperidol.Investigational
BucindololBucindolol may increase the vasoconstricting activities of Ergonovine.Investigational
BufuralolBufuralol may increase the vasoconstricting activities of Ergonovine.Experimental, Investigational
BupranololBupranolol may increase the vasoconstricting activities of Ergonovine.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergonovine.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ergonovine.Approved
CabergolineErgonovine may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Ergonovine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ergonovine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ergonovine.Approved
CandoxatrilThe serum concentration of Ergonovine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Ergonovine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Ergonovine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Ergonovine can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Ergonovine can be increased when it is combined with Carbomycin.Vet Approved
Carboprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Ergonovine.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ergonovine.Approved
CariprazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cariprazine.Approved
CarteololCarteolol may increase the vasoconstricting activities of Ergonovine.Approved
CarvedilolCarvedilol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
CeliprololCeliprolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
CeritinibThe serum concentration of Ergonovine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ergonovine.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Ergonovine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorprothixene.Approved, Withdrawn
ChymostatinThe serum concentration of Ergonovine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Ergonovine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Ergonovine can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Ergonovine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Ergonovine.Approved, Investigational
CirazolineErgonovine may increase the hypertensive activities of Cirazoline.Experimental
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ergonovine.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergonovine.Approved
ClarithromycinThe metabolism of Ergonovine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ergonovine can be decreased when combined with Clemastine.Approved
ClenbuterolErgonovine may increase the hypertensive activities of Clenbuterol.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ergonovine.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Ergonovine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ergonovine.Approved, Vet Approved
ClonidineErgonovine may increase the hypertensive activities of Clonidine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ergonovine.Approved, Nutraceutical
ClotrimazoleThe metabolism of Ergonovine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ergonovine.Approved
CobicistatThe metabolism of Ergonovine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ergonovine.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ergonovine.Approved
ConivaptanThe serum concentration of Ergonovine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ergonovine.Approved
CrizotinibThe metabolism of Ergonovine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergonovine.Approved
CyclosporineThe metabolism of Ergonovine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergonovine.Approved
DabrafenibThe serum concentration of Ergonovine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Ergonovine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ergonovine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergonovine.Investigational
DarunavirThe serum concentration of Ergonovine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ergonovine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ergonovine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ergonovine.Approved
DeferasiroxThe serum concentration of Ergonovine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ergonovine can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ergonovine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Desvenlafaxine.Approved
DetomidineErgonovine may increase the hypertensive activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Ergonovine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineErgonovine may increase the hypertensive activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergonovine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ergonovine.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ergonovine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ergonovine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ergonovine.Approved
DihydroergotamineErgonovine may increase the vasoconstricting activities of Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Ergonovine.Illicit
DiltiazemThe metabolism of Ergonovine can be decreased when combined with Diltiazem.Approved
DipivefrinErgonovine may increase the hypertensive activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Ergonovine.Approved
DobutamineErgonovine may increase the hypertensive activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ergonovine.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Ergonovine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ergonovine.Approved, Investigational, Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Ergonovine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ergonovine.Approved, Investigational
DoxycyclineThe metabolism of Ergonovine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Ergonovine can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Droperidol.Approved, Vet Approved
DroxidopaErgonovine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergonovine.Approved
EcabetThe serum concentration of Ergonovine can be increased when it is combined with Ecabet.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ergonovine.Approved
EfavirenzThe serum concentration of Ergonovine can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Ergonovine can be increased when it is combined with Elafin.Investigational
EletriptanErgonovine may increase the vasoconstricting activities of Eletriptan.Approved, Investigational
EnalaprilThe serum concentration of Ergonovine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Ergonovine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Ergonovine can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Ergonovine can be decreased when it is combined with Enzalutamide.Approved
EphedrineErgonovine may increase the hypertensive activities of Ephedrine.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ergonovine.Approved, Investigational
EpinephrineErgonovine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ergonovine.Approved
ErgotamineErgonovine may increase the hypertensive activities of Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ergonovine.Approved, Investigational
ErythromycinThe serum concentration of Ergonovine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ergonovine.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Ergonovine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the vasoconstricting activities of Ergonovine.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ergonovine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Ergonovine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Ergonovine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ergonovine.Approved
EtilefrineErgonovine may increase the hypertensive activities of Etilefrine.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ergonovine.Approved
EtravirineThe serum concentration of Ergonovine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ergonovine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ergonovine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolErgonovine may increase the hypertensive activities of Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergonovine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ergonovine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Ergonovine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Ergonovine.Approved
FluconazoleThe metabolism of Ergonovine can be decreased when combined with Fluconazole.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergonovine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ergonovine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergonovine.Approved, Investigational
FormoterolErgonovine may increase the hypertensive activities of Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Ergonovine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ergonovine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Ergonovine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Ergonovine can be increased when combined with Fosphenytoin.Approved
FrovatriptanErgonovine may increase the vasoconstricting activities of Frovatriptan.Approved, Investigational
Fusidic AcidThe serum concentration of Ergonovine can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Ergonovine can be increased when it is combined with Gabexate.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Ergonovine.Approved, Investigational
GeldanamycinThe serum concentration of Ergonovine can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Ergonovine.Approved
GM6001The serum concentration of Ergonovine can be increased when it is combined with GM6001.Experimental
GranisetronGranisetron may increase the serotonergic activities of Ergonovine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ergonovine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ergonovine.Withdrawn
GuanabenzErgonovine may increase the hypertensive activities of Guanabenz.Approved
GuanfacineErgonovine may increase the hypertensive activities of Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Ergonovine.Approved
HexoprenalineErgonovine may increase the hypertensive activities of Hexoprenaline.Approved, Withdrawn
HigenamineErgonovine may increase the hypertensive activities of Higenamine.Investigational
HirulogThe serum concentration of Ergonovine can be increased when it is combined with Hirulog.Experimental
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ergonovine.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ergonovine.Approved
IdelalisibThe serum concentration of Ergonovine can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Ergonovine can be increased when it is combined with idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Iloperidone.Approved
ImatinibThe metabolism of Ergonovine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Ergonovine can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergonovine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ergonovine.Approved
IndenololIndenolol may increase the vasoconstricting activities of Ergonovine.Withdrawn
IndinavirThe serum concentration of Ergonovine can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Ergonovine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ergonovine.Approved, Investigational
IsavuconazoniumThe metabolism of Ergonovine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ergonovine.Approved
IsoetarineErgonovine may increase the hypertensive activities of Isoetarine.Approved
IsoflurophateThe serum concentration of Ergonovine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoprenalineErgonovine may increase the hypertensive activities of Isoprenaline.Approved
IsoxsuprineErgonovine may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Ergonovine can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ergonovine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ergonovine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ergonovine.Approved, Vet Approved
IxazomibThe serum concentration of Ergonovine can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Ergonovine can be increased when it is combined with Josamycin.Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ergonovine.Approved
KetoconazoleThe serum concentration of Ergonovine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Ergonovine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Ergonovine can be increased when it is combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the vasoconstricting activities of Ergonovine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ergonovine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ergonovine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ergonovine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ergonovine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ergonovine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ergonovine.Approved
LepirudinThe serum concentration of Ergonovine can be increased when it is combined with Lepirudin.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ergonovine.Approved, Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Ergonovine.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Ergonovine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ergonovine is combined with Levomilnacipran.Approved
LinagliptinThe serum concentration of Ergonovine can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergonovine.Approved, Investigational
LisinoprilThe serum concentration of Ergonovine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideErgonovine may increase the vasoconstricting activities of Lisuride.Approved
LithiumThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lithium.Approved
LofexidineErgonovine may increase the hypertensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ergonovine.Approved
LopinavirThe serum concentration of Ergonovine can be increased when it is combined with Lopinavir.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergonovine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Ergonovine.Approved
LovastatinThe metabolism of Ergonovine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Loxapine.Approved
Lu AA21004Ergonovine may increase the vasoconstricting activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Ergonovine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ergonovine can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lurasidone.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Ergonovine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergonovine.Approved
MedetomidineErgonovine may increase the hypertensive activities of Medetomidine.Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Melperone.Approved
MephentermineErgonovine may increase the hypertensive activities of Mephentermine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mesoridazine.Approved
MetaraminolErgonovine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ergonovine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ergonovine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methotrimeprazine.Approved
MethoxamineErgonovine may increase the hypertensive activities of Methoxamine.Approved
MethyldopaErgonovine may increase the hypertensive activities of Methyldopa.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ergonovine.Approved, Vet Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Ergonovine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Metoclopramide.Approved, Investigational
MetoprololMetoprolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ergonovine.Approved, Illicit
MidodrineErgonovine may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe serum concentration of Ergonovine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ergonovine is combined with Milnacipran.Approved
MirabegronErgonovine may increase the hypertensive activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergonovine.Approved
MitotaneThe serum concentration of Ergonovine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Ergonovine.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ergonovine.Approved
ModafinilThe serum concentration of Ergonovine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Ergonovine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Ergonovine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ergonovine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Ergonovine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololNadolol may increase the vasoconstricting activities of Ergonovine.Approved
NafamostatThe serum concentration of Ergonovine can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Ergonovine can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ergonovine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ergonovine.Approved, Vet Approved
NaphazolineErgonovine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanErgonovine may increase the vasoconstricting activities of Naratriptan.Approved, Investigational
NCX 4016The serum concentration of Ergonovine can be increased when it is combined with NCX 4016.Investigational
NebivololErgonovine may increase the hypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Ergonovine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ergonovine can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ergonovine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ergonovine can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Ergonovine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ergonovine.Approved
NilotinibThe metabolism of Ergonovine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ergonovine.Approved
NitroaspirinThe serum concentration of Ergonovine can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinErgonovine may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ergonovine.Approved
NorepinephrineErgonovine may increase the hypertensive activities of Norepinephrine.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergonovine.Approved
NylidrinErgonovine may increase the hypertensive activities of Nylidrin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Ergonovine.Approved, Investigational
OlaparibThe metabolism of Ergonovine can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Ergonovine can be increased when it is combined with Oleandomycin.Vet Approved
OlodaterolErgonovine may increase the hypertensive activities of Olodaterol.Approved
OmapatrilatThe serum concentration of Ergonovine can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ergonovine.Approved
OndansetronOndansetron may increase the serotonergic activities of Ergonovine.Approved
OrciprenalineErgonovine may increase the hypertensive activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ergonovine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ergonovine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Ergonovine can be increased when it is combined with Otamixaban.Investigational
OxprenololOxprenolol may increase the vasoconstricting activities of Ergonovine.Approved
OxymetazolineErgonovine may increase the hypertensive activities of Oxymetazoline.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ergonovine.Approved, Vet Approved
PalbociclibThe serum concentration of Ergonovine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Ergonovine.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ergonovine.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergonovine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ergonovine.Approved
PenbutololPenbutolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
PentobarbitalThe metabolism of Ergonovine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perazine.Investigational
PergolideErgonovine may increase the vasoconstricting activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Ergonovine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergonovine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergonovine.Approved
PhenobarbitalThe metabolism of Ergonovine can be increased when combined with Phenobarbital.Approved
PhenylephrineErgonovine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineErgonovine may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Ergonovine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Ergonovine can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pimozide.Approved
PindololPindolol may increase the vasoconstricting activities of Ergonovine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipotiazine.Approved
PirbuterolErgonovine may increase the hypertensive activities of Pirbuterol.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ergonovine.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ergonovine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ergonovine.Approved
PosaconazoleThe serum concentration of Ergonovine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the vasoconstricting activities of Ergonovine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ergonovine.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Ergonovine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ergonovine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ergonovine.Approved, Vet Approved
PrimidoneThe metabolism of Ergonovine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Ergonovine can be increased when it is combined with Prinomastat.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ergonovine.Approved
ProcaterolErgonovine may increase the hypertensive activities of Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ergonovine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ergonovine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Propericiazine.Approved
PropranololPropranolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergonovine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ergonovine.Approved
PRX-00023Ergonovine may increase the vasoconstricting activities of PRX-00023.Investigational
PseudoephedrineErgonovine may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ergonovine.Approved
QuinaprilThe serum concentration of Ergonovine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ergonovine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Ergonovine.Approved
RacecadotrilThe serum concentration of Ergonovine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineErgonovine may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Raclopride.Investigational
RactopamineErgonovine may increase the hypertensive activities of Ractopamine.Vet Approved
RamiprilThe serum concentration of Ergonovine can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Ergonovine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ergonovine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rasagiline.Approved
RemikirenThe serum concentration of Ergonovine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Ergonovine.Approved
RifabutinThe metabolism of Ergonovine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ergonovine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ergonovine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ergonovine.Approved, Investigational
RilmenidineErgonovine may increase the hypertensive activities of Rilmenidine.Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ergonovine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ritanserin.Investigational
RitobegronErgonovine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineErgonovine may increase the hypertensive activities of Ritodrine.Approved
RitonavirThe serum concentration of Ergonovine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Ergonovine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanErgonovine may increase the vasoconstricting activities of Rizatriptan.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ergonovine.Approved, Investigational
RomifidineErgonovine may increase the hypertensive activities of Romifidine.Vet Approved
RopiniroleErgonovine may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RoxithromycinThe serum concentration of Ergonovine can be increased when it is combined with Roxithromycin.Approved, Withdrawn
SalbutamolErgonovine may increase the hypertensive activities of Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ergonovine.Approved, Vet Approved
SalmeterolErgonovine may increase the hypertensive activities of Salmeterol.Approved
SaquinavirThe serum concentration of Ergonovine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Ergonovine can be increased when it is combined with Saxagliptin.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergonovine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ergonovine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Ergonovine.Approved
SildenafilThe metabolism of Ergonovine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ergonovine.Approved
SiltuximabThe serum concentration of Ergonovine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ergonovine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Ergonovine can be increased when it is combined with Sitagliptin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ergonovine.Approved
SolabegronErgonovine may increase the hypertensive activities of Solabegron.Investigational
SolithromycinThe serum concentration of Ergonovine can be increased when it is combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ergonovine.Approved, Investigational
SotalolSotalol may increase the vasoconstricting activities of Ergonovine.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ergonovine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ergonovine.Experimental
SpiraprilThe serum concentration of Ergonovine can be increased when it is combined with Spirapril.Approved
SR 58611Ergonovine may increase the hypertensive activities of SR 58611.Investigational
St. John's WortThe serum concentration of Ergonovine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ergonovine can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Ergonovine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulpiride.Approved
SumatriptanErgonovine may increase the vasoconstricting activities of Sumatriptan.Approved, Investigational
SynephrineErgonovine may increase the hypertensive activities of Synephrine.Experimental
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ergonovine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ergonovine.Approved
TapentadolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tapentadol.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Ergonovine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ergonovine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Ergonovine.Approved
TelaprevirThe serum concentration of Ergonovine can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Ergonovine can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Ergonovine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ergonovine.Approved
TerbutalineErgonovine may increase the hypertensive activities of Terbutaline.Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioridazine.Approved
ThiorphanThe serum concentration of Ergonovine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Ergonovine.Approved
TiclopidineThe metabolism of Ergonovine can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the vasoconstricting activities of Ergonovine.Approved
TipranavirThe serum concentration of Ergonovine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineErgonovine may increase the hypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Ergonovine can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ergonovine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ergonovine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ergonovine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergonovine.Approved, Investigational
TrandolaprilThe serum concentration of Ergonovine can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergonovine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ergonovine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergonovine.Approved, Investigational
TrifluoperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergonovine.Approved
TroleandomycinThe serum concentration of Ergonovine can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Ergonovine.Investigational
TulobuterolErgonovine may increase the hypertensive activities of Tulobuterol.Investigational
TylosinThe serum concentration of Ergonovine can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Ergonovine can be increased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Ergonovine can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ergonovine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ergonovine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ergonovine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Ergonovine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ergonovine.Approved
VerapamilThe metabolism of Ergonovine can be decreased when combined with Verapamil.Approved
VilazodoneErgonovine may increase the vasoconstricting activities of Vilazodone.Approved
VildagliptinThe serum concentration of Ergonovine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ergonovine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ergonovine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ergonovine.Approved
VoriconazoleThe serum concentration of Ergonovine can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineErgonovine may increase the vasoconstricting activities of Vortioxetine.Approved
XimelagatranThe serum concentration of Ergonovine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineErgonovine may increase the hypertensive activities of Xylazine.Vet Approved
YM-178Ergonovine may increase the hypertensive activities of YM-178.Investigational
Ym150The serum concentration of Ergonovine can be increased when it is combined with Ym150.Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ergonovine.Approved
ZiprasidoneThe metabolism of Ergonovine can be decreased when combined with Ziprasidone.Approved
ZolmitriptanErgonovine may increase the vasoconstricting activities of Zolmitriptan.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesG02AB03
AHFS Codes
  • 76:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.6971
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8385
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.7295
CYP450 2C9 substrateNon-substrate0.8097
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.6814
CYP450 1A2 substrateNon-inhibitor0.7284
CYP450 2C9 inhibitorNon-inhibitor0.9116
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9228
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9236
Ames testNon AMES toxic0.5743
CarcinogenicityNon-carcinogens0.9353
BiodegradationNot ready biodegradable0.8714
Rat acute toxicity3.3967 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.954
hERG inhibition (predictor II)Inhibitor0.5624
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntramuscular; Intravenous.25 mg
SolutionIntramuscular; Intravenous0.25 mg
TabletOral.2 mg
Prices
Unit descriptionCostUnit
Ergonovine maleate 100% powder676.9USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point162 °CPhysProp
water solubility2.68 mg/mL at 25 °CMEYLAN,WM et al. (1996)
logP0.9Not Available
pKa6.8MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.321 mg/mLALOGPS
logP1.53ALOGPS
logP1.07ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)15ChemAxon
pKa (Strongest Basic)7.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area68.36 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity95.05 m3·mol-1ChemAxon
Polarizability36.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassErgoline and derivatives
Sub ClassLysergic acids and derivatives
Direct ParentLysergamides
Alternative Parents
Substituents
  • Lysergic acid amide
  • Indoloquinoline
  • Benzoquinoline
  • Quinoline-3-carboxamide
  • Pyrroloquinoline
  • Quinoline
  • Isoindole or derivatives
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • Tetrahydropyridine
  • Benzenoid
  • Heteroaromatic compound
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Gibson A, Carvajal A: Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9. [PubMed:2897449 ]
  2. Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, Huang L, Guo Y, Han L, Zheng C, Chen Y: Update of TTD: Therapeutic Target Database. Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91. doi: 10.1093/nar/gkp1014. Epub 2009 Nov 20. [PubMed:19933260 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Moubarak AS, Rosenkrans CF Jr, Johnson ZB: Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9. [PubMed:12583687 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
Comments
comments powered by Disqus
Drug created on April 04, 2007 16:45 / Updated on August 17, 2016 12:23